Novavax’s influenza vaccine meets all goals in study
Novavax, Inc. currently trades at $12.10 and has seen gains of 27.44% in the past month. Novavax, Inc. has seen a decrease in revenue in the past four quarters. Recently, NVAX rose 18.7% yesterday after the company announced positive top-line data from a pivotal phase III study on its nanoparticle seasonal influenza vaccine candidate, NanoFlu, for adult patients aged 65 years and above. The stock rallied 20.3% in the past year against the industry’s decline of 19.9%. NVAX appears to be a greay buy because in March, the Coalition for Epidemic Preparedness (CEPI) awarded initial funding of $4 million to support Novavax’s efforts to develop a COVID-19 vaccine. Both CEPI and the company are in talks regarding additional funding from CEPI to cover the costs through the phase I. Novavax, Inc.’s dividends sit at 0% and has a market cap of $605.47 million. Overall, Novavax, Inc. is a stock you want to keep an eye out for. Yesterday the stock closed at $11.75 leaving investors down 7.66% in the past 24 hours. Novavax, Inc.’s high 1-year forecast is $17 with a low of $13.